About Us
ILLUMISONICS IS A COMPANY BASED ON APPLIED NEW PHYSICS (PARS®) TO ILLUMINATE DEEP DATA
Our proprietary PARS® (Photon Absorption Remote Sensing) technology is a revolution in optical imaging.
Our company is developing and plans to commercialize its PARS® advanced optical imaging systems for a wide range of pre-clinical and clinical applications.
Our proprietary PARS® (Photon Absorption Remote Sensing) technology is a revolution in optical imaging.
Our company is developing and plans to commercialize its PARS® advanced optical imaging systems for a wide range of pre-clinical and clinical applications.
Experienced Leadership
JOHN MACKEY, MD.
CEO Dr. Mackey is a medical oncologist and Professor Emeritus of Oncology at the University of Alberta. In addition to acting as director and clinical advisor to illumiSonics, Dr Mackey brings deep MedTech commercialization experience. He co-founded Pacylex Pharmaceuticals, J2 Endeavours, and SMHeartCard Inc. As Chair of the Alberta Pre-Phase I Program steering committee, he has a highly skilled team committed to bringing new anticancer therapies into clinical testing (www.prephaseone.com). Dr. Mackey has authored or co-authored more than 300 biomedical peer-reviewed publications.
|
GLEN MACKEY
CFO Mr. Mackey is a seasoned corporate executive with extensive experience in marketing, trading, compliance, and financial management in the commodity marketing and financial sectors. Currently Chairman of the board at VRP Farms Ltd., he previously served as Chief Risk and Procurement Officer at NRG Energy, overseeing risk management, procurement, and financial activities. Mackey has also held leadership roles at Nexen Inc., EnCana, Duke Energy, and TD Bank. He is an advisory board member at Rutgers University and a member of the Market Risk Advisory Committee of the Commodity Futures Trading Commission.
|
Management
MIKE BISHOP
Director, Product Dev. and Hardware Architecture Mike Bishop spent 10 years at Apple, most recently as an Engineering Manager in hardware technologies, where he led a team in designing and prototyping biophotonic hardware systems. Before Apple, he was with Christie Digital, where he played a key role in developing the first high-power RGB laser-based cinema projector. Mike holds B.Sc. and M.Sc. degrees in Mechanical Engineering from the University of Waterloo and an MBA from Wilfrid Laurier University. He also holds numerous patents in nanotechnology, optical sensors, optomechanical design, and thermal architectures.
|
KRISTOF SUBRYAN
Director, Software Architecture Kristof Subryan is a software professional with experience in robotics research, medical imaging, education, and commercial software development. He worked 16 years at Apple where, amongst other projects, he managed development of Aperture, software for professional photographers. Prior to Apple he worked for Sun Microsystems where he managed number of large infrastructure projects supporting Sun’s business as well as projects powering large telecom companies. He holds B.Sc. and M.Sc. degrees in Computer Science from University of Manitoba.
|
JILL STEFANELLI, PHD
Advisory Board Member and Consultant in Digital and Molecular Pathology Dr. Stefanelli, a pioneer in precision medicine, brings over 20 years of experience in pathology and molecular diagnostics to illumiSonics. She has held key leadership roles, including President and Chief Business Officer at Paige, where she drove corporate strategy and commercial growth, and led strategic partnerships in life sciences and biomarker development. Previously, she served as Senior VP of Partnerships at Invitae, leading global Companion Diagnostic initiatives. Dr. Stefanelli also established the first Companion Diagnostic program for the OncomineDX assay at Thermo Fisher Scientific and has held positions at Pacific Biosciences, Roche Diagnostics, and the USDA.
|
DEEPAK DINAKARAN, MD.
Director Molecular Imaging Dr. Dinakaran is a radiation oncologist and clinician scientist at Sunnybrook Health Sciences Center in Toronto, Canada. He holds degrees from the University of Toronto, McGill University, the University of British Columbia, and the University of Alberta, with postgraduate training at the NIH. His research focuses on biophotonics, nanoparticle-based therapeutics, and radiotherapy-drug interactions. He pioneered a therapeutic strategy using radiation-activated photodynamic therapy (radioPDT) nanoparticles, leading to a patent, industry licensing, and CIHR funding. Dr. Dinakaran has authored 20+ publications and is a co-investigator on multiple clinical trials with major pharmaceutical partners.
|
Board of Directors
JOHN MACKEY, MD.
CEO & Director Dr. Mackey is a medical oncologist and Professor Emeritus of Oncology at the University of Alberta. In addition to acting as director and clinical advisor to illumiSonics, Dr Mackey brings deep MedTech commercialization experience. He co-founded Pacylex Pharmaceuticals, J2 Endeavours, and SMHeartCard Inc. As Chair of the Alberta Pre-Phase I Program steering committee, he has a highly skilled team committed to bringing new anticancer therapies into clinical testing (www.prephaseone.com). Dr. Mackey has authored or co-authored more than 300 biomedical peer-reviewed publications.
|
GLEN MACKEY
CFO & Director Mr. Mackey is a seasoned corporate executive with extensive experience in marketing, trading, compliance, and financial management in the commodity marketing and financial sectors. Currently Chairman of the board at VRP Farms Ltd., he previously served as Chief Risk and Procurement Officer at NRG Energy, overseeing risk management, procurement, and financial activities. Mackey has also held leadership roles at Nexen Inc., EnCana, Duke Energy, and TD Bank. He is an advisory board member at Rutgers University and a member of the Market Risk Advisory Committee of the Commodity Futures Trading Commission.
|
Our Development and Technology Partners
|
PHOTOMEDICINE LABS
The PhotoMedicine Labs (PML) is a research group in the Department of Systems Design Engineering at the University of Waterloo. Professor Parsin Haji Reza founded PML in September 2018, with the vision of growing it to become a major hub within the fields of biomedical optics and optical imaging. PML is composed of talented graduate students, postdoctoral fellows, scientists, engineers, and clinicians, all working to design and develop innovative medical imaging techniques in the field of digital pathology, oncology, pre-clinical research, drug discovery, and ophthalmology. » PhotoMedicine Labs |